Case study

Rett-like onset in late-infantile neuronal ceroid lipofuscinosis (CLN7) caused by compound heterozygous mutation in the MFSD8 gene and review of the literature data on clinical onset signs

Dana Craiu a,b,*, Octavia Dragostin b,1, Alice Dica c,1, Dorota Hoffman-Zacharska d,2, Monika Gos d,2, Alexandra Eugenia Bastian e,f,3, Mihaela Gherghiceanu g,4, Arndt Rolfs h,i, Nahid Nahavandi i, Mihai Craiu j,k,5, Catrinel Iliescu a,b,6

a “Carol Davila” University of Medicine Bucharest, Department of Neurology, Pediatric Neurology, Psychiatry, Neurosurgery, Discipline Pediatric Neurology, Romania
b Pediatric Neurology Clinic, “Alexandru Obregia” Clinical Psychiatric Hospital, Şos. Bercren 10-12, Sector 4, Bucharest, Romania
c Pediatric Neurology Clinic, Research Department, “Alexandru Obregia” Clinical Psychiatric Hospital, Şos. Bercren 10-12, Sector 4, Bucharest, Romania
d Department of Medical Genetics, Institute of Mother and Child, Kasprzaka 17A, 01-211 Warsaw, Poland
e “Carol Davila” University of Medicine Bucharest, Department II, Dental Medicine, Pathology Discipline, Romania
f Pathology Lab., Colentina University Hospital, Sos Stefan cel Mare 19-21, Sector 2, 020125 Bucharest, Romania
g Ultrastructural Pathology Lab., ‘Victor Babes’ National Institute of Pathology, 99-101 Spl. Independentei, 050096 Bucharest S, Romania
h Albrecht-Kossel-Institute for Neurogenetics, Medical Faculty, University of Rostock, Gehlsheimerstrasse 20, 18157 Rostock, Germany
i Centogene AG, Schillingallee 69, 18057 Rostock, Germany
j “Carol Davila” University of Medicine Bucharest, Department of Pediatrics and Medical Genetics, Discipline Pediatrics, Romania
k Pediatric II Clinic, “Alfred Rusescu” Clinical Pediatric Hospital, Institute of Mother and Child Health, B-dul Lacul Tei No. 120, Sector 2, Bucharest, Romania

* Corresponding author. Pediatric Neurology Clinic, “Alexandru Obregia” Clinical Psychiatric Hospital, Şos. Bercren 10-12, Sector 4, Bucharest, Romania. Tel.: +40 213347994, +40 745830090 (mobile); fax: +40 213347994.
E-mail addresses: dcraiu@yahoo.com (D. Craiu), octaviadragostin@yahoo.com (O. Dragostin), dica_denisa@yahoo.com (A. Dica), dhoffman@wp.pl (D. Hoffman-Zacharska), monika.gos@imid.med.pl (M. Gos), aleca.bastian@yahoo.com (A.E. Bastian), mgherghiceanu@yahoo.com (M. Gherghiceanu), Arndt.Rolfs@centogene.com (A. Rolfs), Nahid.Nahavandi@centogene.com (N. Nahavandi), mcraiu@yahoo.com (M. Craiu), iliescu_catrinel@yahoo.com (C. Iliescu).
1 Tel./fax: +40 213347994.
2 Tel./fax: +48 22 32 77 200.
3 Tel.: +40 21 3173245.
4 Tel.: +40 21 319 45 28, 40 722 692 401 (mobile); fax: +40 21 319 45 28.
5 Tel.: +40 744199063.
6 Tel.: +40 213344266x463.
http://dx.doi.org/10.1016/j.ejpn.2014.07.008
1090-3798/© 2014 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
1. Introduction

The neuronal ceroid-lipofuscinoses (NCLs) are a group of neurodegenerative inherited lysosomal storage disorders characterized by progressive cognitive and motor deterioration, ataxia, visual loss, seizures, and early death. The present proposal for classification, underlying the genetic and clinical heterogeneity, takes into account the responsible gene, precise genetic defect, clinical characteristics (age at onset, presenting symptoms, disease progression), biochemical phenotype and ultrastructural features, functionality and other remarks (additional disabilities, etc.), structured in 7 diagnostic axes, the last 3 being optional. 13 mutated genes have been described so far2–4 as responsible for the classically described NCL phenotypes: congenital, infantile, late-infantile, juvenile, adult. Variant late-infantile NCL (vLINCL) is genetically heterogeneous, with 5 major underlying genes identified so far. CLN7 disease, produced by MFSD8 gene mutations has a rather homogenous phenotype1 with 10–15% patients with an atypical onset or course4,6,7 onset typically occurs between 2 and 11 years of age (mean onset 5 years) with a late-infantile clinical picture showing motor and cognitive decline, seizures, visual loss, ataxia. A Rett-like onset have been described in the infantile CLN1 disease,7,8 but not in CLN7 (one male patient with Turkish variant NCL have been described having stereotyped hand movements associated to an autistic behaviour in the midline, hyperventilation episodes) present at the onset of her condition (age 18 months), features still present at the initial evaluation in our clinic at age 5 years.

Results: MECP2 (methyl CpG binding protein 2) gene mutation was negative. At age 6 years she was readmitted for severe ataxia and blindness, seizures, and severe developmental regression leading to NCL (neuronal ceroid lipofuscinosis) suspicion. EEG showed slow background with IRDA (intermittent rhythmic delta activity). A conjunctive biopsy showed abnormal curvilinear and fingerprint lysosomal deposits, and genetic analysis revealed two heterozygous mutations of MFSD8 gene (c.881C > A p.Thr294Lys and c.754 + 2T > A) each inherited from carrier parents and a heterozygous variant (c.470A>C p.Asp157Ala) of CLN5 gene.

Conclusion: NCL should be suspected and MFSD8 genetic testing should also be considered in patients with Rett like phenotype at onset and negative MECP2 mutation. Such cases should be carefully and frequently re-evaluated in order to avoid delayed diagnosis and offer proper genetic advice to the family. In our knowledge, this might be the first case of CLN7 disease with Rett like onset described in the literature, which developed typical vLINCL clinical phenotype after age 5.5 years. A short review of the literature showing NCL onset modalities is presented.

2. Case presentation

We present a 7 years old female patient, first admitted in our clinic at 5 years old, for evaluation of a global regression. She has had unremarkable perinatal and family history. Both parents are reported as Caucasian and unrelated. Head circumference at birth is not known. She had an under average developmental milestones achievement, but within normal range until age 12 months (head lift at 5 months, sitting acquired at 7 months and she was able to stand around 12 months of age when she made the first steps with aid), independent walking at 16 months. Voluntary grasping was normally developed until age 10–12 months. She produced syllables at age 5 months and she was able to say 3 meaningful words at age 12 months. She subsequently gradually lost cognitive and motor abilities and had difficulties in